Defining The Role Of A Novel Transcriptional Enhancer Element In Regulation Of Prox1 Expression And Endothelial Cell Identity.
Funder
National Health and Medical Research Council
Funding Amount
$706,909.00
Summary
The precise spatial and temporal control of gene expression is regulated by non-coding regions of the genome termed enhancers. Enhancers are crucial to program cell identity and have established roles in development and disease. We have identified a novel enhancer that we hypothesise controls the identity of valve endothelial cells by regulating expression of a master programmer of lymphatic endothelial cell identity, PROX1. Here we will investigate the role of this enhancer during development.
Does A Health In All Policies Approach Improve Health, Well-being And Equity?
Funder
National Health and Medical Research Council
Funding Amount
$968,325.00
Summary
This project will develop understanding of complex policy initiatives for health & well being which operate across government departments. It will do this through a case study of the SA Government’s Health in All Policies approach which aims to get government departments to develop policies which build a healthier population and reduce health inequities. This research will assess that process, report on what helps and hinders and develop research methods suitable for complex policy evaluation.
Cerebral Palsy (CP) is a devastating, common developmental brain disorder once assumed to be due to lack of oxygen at birth. Using our unique Biobank with DNA and clinical data from families with a CP child, we are examining the genetic origins of CP and how genes and risk factors in pregnancy contribute. We will use computer modelling and testing in animals and brain cells, to understand causes of CP and devise predictive, preventative and therapeutic strategies.
Mab Immunotherapies For Myeloid Leukemia Patients With Germline Or Somatic RUNX1 Mutations.
Funder
National Health and Medical Research Council
Funding Amount
$766,995.00
Summary
This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.
Assessing Infrastructure And Contextual Factors In Relation To Cardiometabolic Outcomes In Remote Indigenous Communities: Evidence For Policy Change
Funder
National Health and Medical Research Council
Funding Amount
$1,113,005.00
Summary
Cardiometabolic diseases account for the major burden of morbidity and mortality for Indigenous populations. This study with 75 remote Indigenous communities will be the first to evaluate features of their social, built and physical environments in relation to cardiometabolic risks and diseases. Policy-relevant results will identify features of environments to be targeted to reduce chronic diseases for Indigenous peoples in remote communities.
Testing The Behavioural And Psychosocial Mechanisms Underlying Geographic Variation In Metabolic Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$415,457.00
Summary
This study seeks to assess the mechanisms that explain the link between residential area features and the metabolic syndrome (obesity and high blood pressure, lipids and glucose), related to cardiometabolic diseases. There is more metabolic syndrome in disadvantaged areas but the reasons for this have not been empirically established. We will evaluate behavioural and psychosocialmechanisms that might independently and jointly explain the association between place and metabolic syndrome.